{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:49:02Z","timestamp":1760906942339,"version":"3.44.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.pharma.2009.02.004","type":"journal-article","created":{"date-parts":[[2009,3,30]],"date-time":"2009-03-30T14:42:09Z","timestamp":1238424129000},"page":"203-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vaccins du futur"],"prefix":"10.1016","volume":"67","author":[{"given":"M.P.","family":"Girard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2009.02.004_bib1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/nm1209","article-title":"Vaccines: past, present and future","volume":"11","author":"Plotkin","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.pharma.2009.02.004_bib2","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.vaccine.2006.11.032","article-title":"Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998\u20132006)","volume":"25","author":"Oosterhuis-Kafeja","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2009.02.004_bib3","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1016\/j.vaccine.2008.04.040","article-title":"Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000\u20132005","volume":"26","author":"Harboe","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2009.02.004_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/CIA.S1225","article-title":"Zoster vaccine live for the prevention of shingles in the elderly patient","volume":"3","author":"Zussman","year":"2008","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.pharma.2009.02.004_bib5","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1016\/j.vaccine.2007.01.102","article-title":"Rotavirus vaccines\u2013an update","volume":"25","author":"Dennehy","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2009.02.004_bib6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0140-6736(08)60524-3","article-title":"Efficacy and safety of an oral live attenuated human Rotavirus vaccine against Rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase\u00a0III study","volume":"371","author":"Linhares","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2009.02.004_bib7","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.vaccine.2005.09.001","article-title":"Prophylactic HPV vaccines: reducing the burden of HPV-related diseases","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2009.02.004_bib8","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human Papillomavirus (types 6,11,16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2009.02.004_bib9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/IAI.70.2.672-678.2002","article-title":"Failure of the Mycobacteriumbovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis","volume":"70","author":"Brandt","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.pharma.2009.02.004_bib10","doi-asserted-by":"crossref","first-page":"S482","DOI":"10.1086\/521121","article-title":"Tugela Ferry Care and Research (TF CARES) Collaboration. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa","volume":"196","author":"Andrews","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pharma.2009.02.004_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1472-9792(02)00080-X","article-title":"Prospects for a better vaccine against tuberculosis","volume":"83","author":"Reed","year":"2003","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.pharma.2009.02.004_bib12","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1016\/j.vaccine.2005.07.045","article-title":"A review of vaccine research and development: tuberculosis","volume":"23","author":"Girard","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2009.02.004_bib13","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1038\/nm1221","article-title":"Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis","volume":"11","author":"Kaufmann","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.pharma.2009.02.004_bib14","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1016\/j.vaccine.2006.03.017","article-title":"The live MycobacteriumtuberculosisphoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs","volume":"24","author":"Martin","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2009.02.004_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrmicro1419","article-title":"Advances in tuberculosis vaccine strategies","volume":"4","author":"Skeiky","year":"2006","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.pharma.2009.02.004_bib16","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.4049\/jimmunol.172.12.7618","article-title":"Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein","volume":"172","author":"Skeiky","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.pharma.2009.02.004_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2172-9-38","article-title":"Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes","volume":"9","author":"Rosada","year":"2008","journal-title":"BMC Immunol"},{"key":"10.1016\/j.pharma.2009.02.004_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tube.2004.09.015","article-title":"Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials","volume":"85","author":"McShane","year":"2005","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.pharma.2009.02.004_bib19","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1086\/590185","article-title":"Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa","volume":"198","author":"Hawkridge","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pharma.2009.02.004_bib20","doi-asserted-by":"crossref","first-page":"e1052","DOI":"10.1371\/journal.pone.0001052","article-title":"Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials","volume":"2","author":"Pathan","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pharma.2009.02.004_bib21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrmicro1069","article-title":"Urbanization, malaria transmission and disease burden in Africa","volume":"3","author":"Hay","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.pharma.2009.02.004_bib22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pt.2006.06.006","article-title":"Mapping the global extent of malaria in 2005","volume":"22","author":"Guerra","year":"2006","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.pharma.2009.02.004_bib23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0140-6736(03)15267-1","article-title":"Malaria vaccine developments","volume":"363","author":"Moorthy","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2009.02.004_bib24","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.vaccine.2006.09.074","article-title":"A review of human vaccine research and development: malaria","volume":"25","author":"Girard","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2009.02.004_bib25","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0140-6736(04)17223-1","article-title":"Efficacy of the RTS,S\/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial","volume":"364","author":"Alonso","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2009.02.004_bib26","first-page":"83","article-title":"Malaria: deploying a candidate vaccine (RTS,S\/AS02A) for an old scourge of humankind","volume":"9","author":"Alonso","year":"2006","journal-title":"Int Microbiol"},{"key":"10.1016\/j.pharma.2009.02.004_bib27","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1371\/journal.pmed.0010033","article-title":"A randomised, double-blind, controlled vaccine efficacy trial of DNA\/MVA ME-TRAP against malaria infection in Gambian adults","volume":"1","author":"Moorthy","year":"2004","journal-title":"PLoS Med"},{"key":"10.1016\/j.pharma.2009.02.004_bib28","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.1128\/IAI.00590-06","article-title":"A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodiumfalciparum sporozoite challenge","volume":"74","author":"Dunachie","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.pharma.2009.02.004_bib29","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1371\/journal.pctr.0010029","article-title":"A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya","volume":"1","author":"Bejon","year":"2006","journal-title":"PLoS Clin Trials"},{"key":"10.1016\/j.pharma.2009.02.004_bib30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.vaccine.2005.11.037","article-title":"Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodiumfalciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya","volume":"25","author":"Stoute","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2009.02.004_bib31","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1128\/IAI.73.6.3677-3685.2005","article-title":"Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodiumfalciparum malaria","volume":"73","author":"Malkin","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.pharma.2009.02.004_bib32","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1128\/IAI.73.12.8017-8026.2005","article-title":"Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen","volume":"73","author":"Audran","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.pharma.2009.02.004_bib33","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1016\/j.vaccine.2006.06.081","article-title":"Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodiumfalciparum in a phase 1 malaria vaccine trial","volume":"25","author":"Hermsen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2009.02.004_bib34","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1086\/339342","article-title":"A recombinant blood-stage malaria vaccine reduces Plasmodiumfalciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea","volume":"185","author":"Genton","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pharma.2009.02.004_bib35","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nm.1850","article-title":"Effective induction of high-titer antibodies by viral vector vaccines","volume":"14","author":"Draper","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.pharma.2009.02.004_bib36","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1086\/499314","article-title":"Clinical case definitions and malaria vaccine efficacy","volume":"193","author":"Rogers","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pharma.2009.02.004_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ni1296","article-title":"HIV vaccine design: insights from live attenuated SIV vaccines","volume":"7","author":"Koff","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pharma.2009.02.004_bib38","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1016\/j.vaccine.2006.02.031","article-title":"A review of vaccine research and development: the human immunodeficiency virus (HIV)","volume":"24","author":"Girard","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2009.02.004_bib39","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nature01188","article-title":"HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites","volume":"420","author":"Kwong","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.pharma.2009.02.004_bib40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/ni0304-233","article-title":"HIV vaccine design and the neutralizing antibody problem","volume":"5","author":"Burton","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pharma.2009.02.004_bib41","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev.immunol.24.021605.090557","article-title":"GP120: target for neutralizing HIV-1 antibodies","volume":"24","author":"Pantophlet","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.pharma.2009.02.004_bib42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature07159","article-title":"Molecular architecture of native HIV-1 gp120 trimers","volume":"455","author":"Liu","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.pharma.2009.02.004_bib43","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.1161121","article-title":"Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection","volume":"321","author":"Santiago","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.pharma.2009.02.004_bib44","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1126\/science.299.5611.1290","article-title":"Public health. AIDS vaccine trial produces disappointment and confusion","volume":"299","author":"Cohen","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.pharma.2009.02.004_bib45","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1086\/428405","article-title":"Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial","volume":"191","author":"Gilbert","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pharma.2009.02.004_bib46","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","article-title":"HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells","volume":"107","author":"Betts","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2009.02.004_bib47","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1073\/pnas.0611244104","article-title":"HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype","volume":"104","author":"Saez-Cirion","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharma.2009.02.004_bib48","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20070784","article-title":"Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctio nality, and clonal turnover","volume":"204","author":"Almeida","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharma.2009.02.004_bib49","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1126\/science.283.5403.857","article-title":"Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes","volume":"283","author":"Schmitz","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.pharma.2009.02.004_bib50","doi-asserted-by":"crossref","first-page":"18648","DOI":"10.1073\/pnas.0709198104","article-title":"Protection against simian\/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid","volume":"104","author":"Boyer","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharma.2009.02.004_bib51","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1016\/j.vaccine.2005.08.017","article-title":"Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation","volume":"24","author":"Otten","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2009.02.004_bib52","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1016\/j.vaccine.2008.02.036","article-title":"Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques","volume":"26","author":"Hirao","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2009.02.004_bib53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1084\/jem.20072681","article-title":"The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?","volume":"205","author":"Sekaly","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharma.2009.02.004_bib54","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nm.f.1759","article-title":"Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans","volume":"14","author":"Watkins","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.pharma.2009.02.004_bib55","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1126\/science.1161000","article-title":"HIV vaccine research: the way forward","volume":"321","author":"Fauci","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.pharma.2009.02.004_bib56","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm.f.1774","article-title":"CD8+ T cell efficacy in vaccination and disease","volume":"14","author":"Appay","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.pharma.2009.02.004_bib57","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1086\/525046","article-title":"Simian immuno deficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection","volume":"197","author":"Li","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pharma.2009.02.004_bib58","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/JCM.01729-07","article-title":"Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis","volume":"46","author":"Gori","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.pharma.2009.02.004_bib59","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/path.2276","article-title":"Immune activation and inflammation in HIV-1 infection: causes and consequences","volume":"214","author":"Appay","year":"2008","journal-title":"J Pathol"},{"key":"10.1016\/j.pharma.2009.02.004_bib60","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1172\/JCI33034","article-title":"Understanding the benign nature of SIV infection in natural hosts","volume":"117","author":"Silvestri","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharma.2009.02.004_bib61","doi-asserted-by":"crossref","first-page":"8307","DOI":"10.1128\/JVI.00520-08","article-title":"Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation","volume":"82","author":"Chase","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.pharma.2009.02.004_bib62","doi-asserted-by":"crossref","unstructured":"Report of an international workshop, 28\u201330October2007. Mucosal immunity and HIV\/AIDS vaccines. Vaccine 2008;26:3969\u201377.","DOI":"10.1016\/j.vaccine.2008.04.051"},{"key":"10.1016\/j.pharma.2009.02.004_bib63","first-page":"11","article-title":"Engineering Immunity","volume":"12","author":"Von Bubnoff","year":"2008","journal-title":"IAVI Rep"},{"key":"10.1016\/j.pharma.2009.02.004_bib64","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3201\/eid1407.071412","article-title":"Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997\u20132006","volume":"14","author":"Schwartz","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.pharma.2009.02.004_bib65","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(07)61687-0","article-title":"Dengue","volume":"370","author":"Halstead","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2009.02.004_bib66","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.qco.0000244047.31135.fa","article-title":"Immunopathological mechanisms in dengue and dengue hemorrhagic fever","volume":"19","author":"Green","year":"2006","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.pharma.2009.02.004_bib67","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.icb.7100008","article-title":"Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF\/DSS)","volume":"85","author":"Pang","year":"2007","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.pharma.2009.02.004_bib68","article-title":"Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults","volume":"4","author":"Sun","year":"2008","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.pharma.2009.02.004_bib69","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/427780","article-title":"rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers","volume":"191","author":"Durbin","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pharma.2009.02.004_bib70","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/vim.2006.19.10","article-title":"Development of a live attenuated dengue virus vaccine using reverse genetics","volume":"19","author":"Blaney","year":"2006","journal-title":"Viral Immunol"},{"key":"10.1016\/j.pharma.2009.02.004_bib71","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cimid.2007.07.011","article-title":"Towards a dengue vaccine: progress to date and remaining challenges","volume":"31","author":"Guy","year":"2008","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.pharma.2009.02.004_bib72","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.mib.2006.07.003","article-title":"Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach","volume":"9","author":"Mora","year":"2006","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.pharma.2009.02.004_bib73","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharma.2009.02.004_bib74","first-page":"353","article-title":"Les vaccins contre les Papillomavirus","volume":"10","author":"Coursaget","year":"2006","journal-title":"Virologie"},{"key":"10.1016\/j.pharma.2009.02.004_bib75","first-page":"1","article-title":"Advisory Committee on Immunization Practices (ACIP). Quadrivalent human Papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.pharma.2009.02.004_bib76","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1038\/nm1210","article-title":"Targeting the innate immune response with improved vaccine adjuvants","volume":"11","author":"Pashine","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.pharma.2009.02.004_bib77","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.vaccine.2008.03.006","article-title":"Report of the third meeting on \u201cinfluenza vaccines that induce broad spectrum and long-lasting immune responses\u201d, World Health Organization, Geneva, Switzerland, 3\u20134December2007","volume":"26","author":"Girard","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2009.02.004_bib78","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.vaccine.2007.11.054","article-title":"Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice","volume":"26","author":"Wack","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2009.02.004_bib79","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nri1728","article-title":"Immunization without needles","volume":"5","author":"Mitragotri","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharma.2009.02.004_bib80","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1016\/j.vaccine.2007.01.043","article-title":"Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study","volume":"25","author":"McKenzie","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.pharma.2009.02.004_bib81","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1086\/590434","article-title":"Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial","volume":"198","author":"Holland","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pharma.2009.02.004_bib82","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1038\/nm1225","article-title":"Introducing new vaccines into developing countries: obstacles, opportunities and complexities","volume":"11","author":"Clemens","year":"2005","journal-title":"Nat Med"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450909000108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450909000108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:27:39Z","timestamp":1757719659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450909000108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0003450909000108"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2009.02.004","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccins du futur","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2009.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}